These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27904739)

  • 21. Dose selection of siltuximab for multicentric Castleman's disease.
    Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
    Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment outcome of Castleman's disease: A real-world experience.
    Min GJ; Jeon YW; Kim TY; Kwag DH; Lee JH; Lee JY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
    Front Oncol; 2022; 12():974770. PubMed ID: 35992883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Unusual Presentation of Multiple Sclerotic Bone Lesions in Unicentric Castleman's Disease.
    Balapanga S; Kalyan Kumar Reddy A; D J S; Thirupathi MSV
    Cureus; 2024 Jul; 16(7):e63738. PubMed ID: 39100061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
    van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
    J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current diagnosis and treatment of Castleman's disease.
    González García A; Moreno Cobo MÁ; Patier de la Peña JL
    Rev Clin Esp (Barc); 2016 Apr; 216(3):146-56. PubMed ID: 26749192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
    Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
    Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unicentric Castleman's disease of abdomen.
    Shah D; Darji P; Lodha S; Bolla S
    J Radiol Case Rep; 2013 Mar; 7(3):26-33. PubMed ID: 23705043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution.
    Jiang JP; Shen XF; Du JF; Guan WX
    Oncol Lett; 2018 Feb; 15(2):2407-2412. PubMed ID: 29434951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rare presentation of unicentric Castleman's disease in the parotid gland.
    Reece B; Ord R; Papadimitriou J
    J Oral Maxillofac Surg; 2012 Sep; 70(9):2114-7. PubMed ID: 22305675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicentric Castleman's disease: a challenging diagnosis.
    Műzes G; Sipos F; Csomor J; Sréter L
    Pathol Oncol Res; 2013 Jul; 19(3):345-51. PubMed ID: 23516126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease.
    Ebisawa K; Shimura A; Honda A; Masamoto Y; Nakahara F; Kurokawa M
    Leuk Lymphoma; 2021 Mar; 62(3):614-619. PubMed ID: 33076723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicentric Castleman's disease: Report of three cases.
    Guazzaroni M; Bocchinfuso F; Vasili E; Lacchè A; Ranalli T; Garipoli A; Di Tosto F; Floris R
    Radiol Case Rep; 2019 Mar; 14(3):328-332. PubMed ID: 30581518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
    Mohammed A; Janku F; Qi M; Kurzrock R
    J Med Case Rep; 2015 Feb; 9():45. PubMed ID: 25884809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Siltuximab: first global approval.
    Markham A; Patel T
    Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible Association of Multicentric Castleman's Disease with Autoimmune Lymphoproliferative Syndrome.
    Minemura H; Tanino Y; Ikeda K
    Biores Open Access; 2018; 7(1):47-51. PubMed ID: 29682404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-Existence of Multicentric Castleman's Disease and Kaposi's Sarcoma.
    Yaghoobi R; Pazyar N; Tavakoli S
    Indian J Dermatol; 2015; 60(3):323. PubMed ID: 26120185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients.
    Ye B; Gao SG; Li W; Yang LH; Zhao SH; Ma K; Zhu XL; Liu XY; Sun KL
    Med Oncol; 2010 Dec; 27(4):1171-8. PubMed ID: 19937164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.